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INTRODUCTION
The problem
The increasing introduction of new genetic technologies in the 
investigation of patients is creating much new information. This 
raises important issues related to the communication of the 
potential health significance of new findings (e.g., new infor-
mation about the natural history of a condition; surveillance 
or treatments available; improved diagnostic accuracy, such as 
a new test; or new information about previously uncertain test 
results, such as classification of a variant of unknown signifi-
cance). This might mean that patients examined and tested in 
the past could now be offered more informative testing. As a 
result, questions may arise about whether health-care profes-
sionals, such as clinical genetics specialists, have a responsibility 
or duty to recontact former patients. Innovations in genomic 
medicine can have significant implications for patients and fam-
ilies regarding health, reproductive decisions, lifestyle choices, 
employment, and psychosocial well-being. However, recontact-
ing patients may also affect them negatively, potentially caus-
ing anxiety and concerns over health and economic activity, 
and they may consider it an intrusion of privacy.1 Recontacting 
patients has been raised as a major issue in medical genetics, 
but its importance will become even more widespread with 
the increasing integration of genomics in medicine.2 Clarifying 
the issues of whether and how recontacting in clinical genetics 
should be implemented is of importance to the current infor-
mation revolution in health care.3
Policy/guidelines
There is no professional consensus in clinical genetics about 
whether, or how, former patients should be recontacted when 
new genetic information relevant to them or their family 
members arises from the use of new technologies. A survey of 
regulations and practices of genetic counseling in 38 European 
countries found that recontacting was among the least covered 
topics in both national legislation and applied practice guide-
lines.4 The only guideline currently available is a statement orig-
inally published in 1999 by the American College of Medical 
Genetics.5 This document highlights the logistical difficulties 
of locating and recontacting former patients, and it identifies 
the primary-care provider—the specialist with the task of pro-
viding continuing care, such as the general practitioner (GP) 
in the UK National Health Service (NHS)—as the principal 
responsible health-care provider to alert patients to the need 
for recontact if necessary. Genetics service providers would be 
responsible for providing clinical updates to patients in rare 
cases in which they are offering continuing care. The statement 
also suggests that patients be appropriately advised to update 
their primary-care provider or the genetics service provider if 
relevant changes in their lives occur, such as pregnancy.5 The 
2008 revision of the statement recognized that, with the uptake 
of next-generation sequencing, testing laboratories may now be 
in a position to know about changes in interpretation of vari-
ants whose significance had previously been unknown (former 
variant of unknown significance) or about reclassifications of 
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previously classified variants, and they should make an effort 
to contact relevant health-care providers if new information 
changes the previous clinical interpretation of a sequence 
variant.6
systematic review of recontacting literature
The only systematic review of recontacting literature7 identi-
fied 61 articles published between 1991 and 2014 that explored 
ethical, legal, social, psychological, clinical, and practical issues. 
The review identified a divergence of expectations about who 
is responsible for keeping patients up to date with relevant 
information. While patients tend to assign this responsibility 
solely to health-care professionals—especially genetics service 
providers—health-care professionals tend to think this respon-
sibility should be shared by patients.8–10 The review also showed 
that, although most patients want to be recontacted, not all do, 
because of the potential for strong emotional reactions to such 
recontact.11,12
Most authors identified a clash between the ethical desirabil-
ity and the practical difficulty of recontacting. The most com-
mon practical barriers to recontacting mentioned are lack of 
infrastructure for tracking data for former patients (e.g., digi-
talization of databases);13 lack of time and resources (e.g., staff, 
money) to perform recontacting;8,9,14 and not having patients’ 
current addresses.15
Suggestions for overcoming these barriers include implement-
ing digital communication systems between laboratory, clinicians, 
and patients;14 involving patients in the processes of recontact-
ing;10,16 and involving patient support or advocacy groups.8,17
Need for more empirical evidence
The authors of the systematic review suggest that more empiri-
cal evidence is needed to advance the discussion about whether 
and how recontacting should be implemented.7 There is limited 
empirical evidence concerning the perspectives of health-care 
professionals and patients on recontacting or what is occurring 
in clinical practice. There is an urgent need for more research 
on the practical and ethical implications for health-care systems 
regarding recontacting recommendations or guidelines. To begin 
to provide such empirical evidence, we conducted a survey of 
clinical genetic services in the United Kingdom regarding their 
current recontacting practices.
MATeRIALs AND MeTHODs
The survey
The survey we conducted is part of an ongoing study that inves-
tigates: the place of recontacting in current clinical practice in 
the NHS in the United Kingdom; the ethical, legal, and social 
issues raised; and the expectations of patients and health-care 
 professionals concerning recontacting (study website: http://
ex.ac.uk/mgc). The main objective of the survey reported here was 
to ascertain whether and how recontacting occurs in the United 
Kingdom. The topic areas were identified from debates in the rel-
evant literature. The questions were developed from relevant lit-
erature, the clinical experience of members of the research team, 
and a pilot survey on recontacting conducted by some members 
of the team in 2011 as part of the “Development of a Draft NHS 
Information Standard for Genetics” by the National Genetics 
Reference Laboratory in Manchester, England  (http://www. 
ngrl.org.uk/Manchester/newsitem/project-develop-draft-nhs-
information-standard-genetics-launched). The questions were 
further refined by pilot testing the survey with clinical genetics 
service providers.
The Web-based survey, designed using the Bristol Online 
Survey tool, was administered between October 2014 and July 
2015. A link to the survey was circulated via an e-mail invi-
tation to the clinical leads of the United Kingdom’s 23 clinical 
genetics services, with a follow-up e-mail sent to senior clini-
cal genetics staff. The landing page of the survey site contained 
information about the study and the research team, and it 
invited respondents to discuss the survey with colleagues in 
their service before completing it.
The survey included closed and open questions with expand-
able text boxes to elicit explanatory comments, and examples. 
This combination of closed and open questions allowed the 
research team to collect both quantitative and qualitative data. 
Free-text responses from the survey were analyzed using the-
matic analysis.18 The survey is provided in the Supplementary 
Information online.
The study was approved by the University of Exeter’s Social 
Sciences and International Studies Ethics Committee.
ResULTs
Respondent characteristics
Twenty of the 23 clinical genetics services in the United Kingdom 
(for a complete list of clinical genetics services, including labo-
ratories, in the United Kingdom visit:  http://www.bsgm.org.uk/
information-education/genetics-centres/) completed the  survey, 
from all four nations comprising the United Kingdom. Of the 20 
respondents who completed the survey (one per service), nine 
were consultant geneticists, seven were consultant genetic coun-
selors, and the remaining four were genetic counselors.
Recontacting experiences and practices
The majority of the services (19/20) reported recontacting 
patients and relevant family members because of significant 
new information. However, 16 of 20 services indicated that 
recontacting occurred on an occasional basis. Only three ser-
vices reported that they routinely recontact former patients.
A variety of reasons were given for having recontacted 
patients (see Table 1). The most common were availability of 
new tests or new results; new clinical guidance; and reclassifica-
tion of a variant of unknown significance. Table 1 reports the 
main themes from respondents’ answers, with some quotations 
to illustrate each theme.
Only seven services responded that they have developed 
recontacting procedures; three of these were the centers that 
responded that they routinely recontact former patients. The 
procedures reported varied across these centers; there was no 
significant pattern. Common across these responses was the 
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mention of a lack of a codified procedure for recontacting. Two 
centers reported that they inform a patient’s GP or pediatrician 
as appropriate; the two others reported that they inform the 
patient directly (via letter or telephone call). The three remain-
ing centers mentioned that they use clinical databases that are 
held by NHS services (when undergoing testing, patients con-
sent to being in the database and indicate whether they wish 
to be recontacted). However, one of these three centers added 
that they were experiencing problems with their clinical data-
bases—as a result of having moved to electronic notes—and 
that they were using external databases as well.
“Triggers” for recontacting
We asked about the type of information that would be suffi-
ciently relevant to trigger recontacting (giving the example of 
relevance based on clinical actionability of the information or 
on its analytic validity). The majority of the services (14/20) 
indicated that one of the most important elements would be 
clinical actionability, i.e., information that has an impact on 
the clinical management of the patient and the patient’s family. 
One service added that in practice they would recontact only 
if new information relates to a small group or an individual 
patient, because of the workload of recontacting large numbers 
of patients. Other common answers included the publication of 
new or revised guidelines or new laboratory reports.
Use of clinical databases
The majority of the responding centers (18/20) use existing 
clinical databases rather than bespoke recontacting systems for 
recontacting purposes. Of these, nine answered that they use 
the databases mainly to identify patients; the other nine used 
them to review notes and/or to flag patients for recontacting. 
The clinical database respondents referred to are databases held 
by the UK NHS. They are used mainly for clinical purposes, but 
sometimes they are used to identify patients for research. Their 
current format is mixed (some centers use electronic versions; 
others use paper-based versions).
Recording of patient preferences
The majority of services (12/20) indicated they do not routinely 
ask patients about their recontacting preferences as part of the 
procedure for obtaining informed consent for genetic test-
ing. Of these, six services responded that they record patients’ 
recontacting preferences systematically, six responded that they 
do so only occasionally, and the remaining eight responded 
that they do not record patients’ preferences at all. Consent 
forms for genetic testing vary across the services in the United 
Kingdom. Six services said they used consent forms that give 
the option to patients to express their recontacting preferences. 
However, as one of these respondents added, consent forms are 
not always used in clinical practice (Table 2).
Seven services stated that the main reasons for not record-
ing patients’ preferences—or for not mentioning the possibility 
of recontact to patients at all—were lack of resources available 
to offer a recontacting service and concern about raising unre-
alistic expectations in patients. Four services mentioned their 
“open-door policy,” whereby clinicians encourage the patient to 
get back in touch with the genetics department from time to 
time to check if there are advances or to update clinicians about 
important changes in the family.
When asked hypothetically if there were reasons to recon-
tact patients even when patients had indicated they would 
not want to be recontacted, a majority of services (14/20) 
responded that they would. In line with previous answers 
Table 1 Most common reasons for recontacting patients and relevant family members (grouped by themes)
Theme Quotations
Availability of new genetic tests or 
new results
“If a new (or improved) testing technique becomes available, for example review of patients who had limited BRCA 
testing, when full analysis became available some were recontacted and asked if they wanted a full screen”
Family follow-up “A new family member has been referred after a long period of time, prompting a review of the file and 
recontacting the family” and “If a result is issued on a deceased individual”
Reclassification of variants of 
unknown significance
“A specific result is re-classified as more (or less) pathogenic and a clinician may decide to recontact a patient(s) 
found to have this mutation to update them on this new information. This is more ad hoc than systematic at the 
present time”
New clinical guidance “New recommendations for gene carriers”
Reproductive relevance “Follow up for teenager for condition of reproductive relevance”
Table 2 Number of centers that ask and record patient recontacting preferences
Asking about patient recontacting preferences Number
Centers that routinely ask patients whether they would like to be recontacted as part of the procedure for obtaining informed consent 8
Centers that do not routinely ask patients whether they would like to be recontacted as part of the procedure for obtaining informed consent 12
Recording patient recontacting preferences Number
Centers that record patient recontacting preferences—systematically 6
Centers that record patient recontacting preferences—occasionally 6
Centers that do not record patient recontacting preferences 8
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about the type of information that would trigger recontact-
ing, the main reason provided was new information that 
may have clinical implications for patients and family mem-
bers. The GP was explicitly mentioned by four respondents 
as a (first) point of contact to involve in this process. One 
respondent argued that patients’ decisions not to be recon-
tacted could not necessarily anticipate the specific infor-
mation subsequently available and therefore might be an 
insufficiently informed refusal.
Of the six services stating that they would respect patients’ 
preference not to be recontacted, one added that if new infor-
mation was likely to have significant implications for a family 
member, then they would inform the patient’s GP; two men-
tioned the possibility of seeking external advice, e.g., from 
the Medical Defence Union or the Genethics Club  (http://
www.ndph.ox.ac.uk/research/ethox-centre/research-projects/
clinical-ethics/the-genehthics-club), a national forum in 
which health professionals discuss practical ethical problems 
encountered in the working lives of clinical genetics depart-
ments in the United Kingdom. One respondent made the 
point that, although patients should not be recontacted if they 
clearly expressed this preference, in practice very few patients 
would be definite about their preferences.
Implementation of recontacting systems
A slight majority of services (11/20) were unsure about whether 
routine recontacting systems should be implemented. Of the 
remaining services, five indicated that they should be imple-
mented and four said that they should not be.
The main arguments in favor of implementing systems 
for recontacting revolved around the ideas that this would 
improve the quality of care received by patients, it would 
increase patients’ autonomy, and it might reduce the potential 
for litigation. We report here some illustrative quotations.
“New information may help reduce the risk of disease/
mortality to other family members—e.g. where a mutation 
is identified—screening and treatment may be offered to 
those at risk.” 
“Technology and knowledge are increasing rapidly and 
what was known or possible even a short time ago may 
well be different and allow individuals more choice or bet-
ter risk assessment or treatment.” 
One respondent also noted that clinical genetics would be 
the only medical specialty in a position to offer recontact-
ing. Another respondent highlighted that having recontacting 
mechanisms in place would facilitate the process.
Among the arguments against the implementation of recon-
tacting systems, lack of resources was again mentioned and 
linked to equitable provision of services within the NHS. 
Another common argument was that patients should be 
encouraged to be more responsible for their health and share 
the responsibility with clinicians to keep current with relevant 
medical information.
Legal implications were also mentioned as an argument 
against the implementation of recontacting systems. Specifically, 
the concern was that introducing such systems would create a 
standard practice and that failure to recontact could then be 
seen as negligent.
Concern was expressed by one service that recontacting 
might cause anxiety for patients and family members; another 
service mentioned that recontacting would be more difficult to 
implement because genetic testing is increasingly ordered by 
mainstream medical specialties. Finally, one service said that 
the time frame for recontacting responsibilities would need 
clarification; for example, for how many years from the genetic 
test would such a responsibility apply?
DIsCUssION
This was the first study in the United Kingdom to explore cur-
rent recontacting practices in clinical genetic services.
Recontacting occurs, but on an ad hoc basis
The majority of UK services reported that they recontact patients 
and family members, confirming the significance of recontact-
ing for good quality of care in clinical practice. The majority 
of respondents indicated that “clinical actionability” of the 
new information is the main reason to recontact. Respondents’ 
answers also suggest that recontacting is becoming more 
important as clinical whole-genome approaches deliver many 
more genetic variants for interpretation. Recontacting tends to 
occur in an ad hoc fashion when an event triggers clinicians to 
review a file, rather than systematically as part of routine clini-
cal practice.
Procedures vary greatly across the United Kingdom
Our findings suggest that there are no standardized recontacting 
practices operating in the United Kingdom. This diversity may 
be the result of historical and resources allocation differences. 
Overall, the fact that recontacting does occur but not in a stan-
dardized fashion reflects the tension identified in prior research 
between the desirability of recontacting and the current lack of 
mechanisms and resources to offer it more systematically, or at 
all, resulting in unequal recontacting service provision across 
the country.8,19 Only a few centers that recontact patients have 
developed systematic recontacting procedures, but these pro-
cedures vary.
We also found considerable diversity in practices regarding 
the use of clinical genetic databases for recontacting purposes 
(e.g., to retrieve patients’ contact details, to review notes, to 
flag patients for recontacting) and regarding how and whether 
patients’ recontacting preferences are recorded.
Patients’ preferences and professionals’ responsibility
Our findings suggest tension between respecting patients’ pref-
erences to not be recontacted (i.e., their right not to know) and 
the responsibility or duty of care of health-care profession-
als toward patients and family members. Although very few 
clinical genetics services reported that they record patients’ 
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recontacting preferences systematically, in response to a hypo-
thetical question many services responded that there were cir-
cumstances in which they would recontact patients and family 
members even if the patients had indicated they would not 
want them to do so. These circumstances were related to the 
emergence of new, clinically actionable information that could 
have an impact on the health management of the patient or 
family members. Respondents’ views appear to be in line with 
the European Society of Human Genetics recommendations 
on the use of whole-genome sequencing in health care,20 par-
ticularly with the recommendation that “Patients’ claims to a 
right not to know do not automatically over-ride professional 
responsibilities when the patient’s own health or that of his or 
her close relatives are at stake” (p. 583).
Implementation of recontacting
Finally, although the majority of respondents indicated that 
recontacting occurs in their genetic centers, albeit in a nonsys-
tematic way, more than half were unsure about whether recon-
tacting systems should be implemented. This finding suggests 
that a thorough evaluation of the desirability, efficacy, equita-
bility, and sustainability of potential recontacting systems in 
the NHS would be necessary before deciding whether and how 
to implement such a service, or before suggesting guidelines. 
Agnosticism toward the implementation of recontacting sys-
tems was accompanied, for some, by the suggestion of greater 
patient involvement in the process of recontacting. This idea 
was supported as promoting patient autonomy while circum-
venting resource and infrastructural barriers that may prevent 
health-care professionals from offering efficient recontact-
ing services. Some framed this idea as being less paternalistic 
than a clinician-driven implementation model in which the 
responsibility for keeping patients updated is placed solely on 
 health-care professionals. However, it is important to point 
out that a clinician-driven implementation model would not 
be paternalistic if patients choose it. Further, shifting respon-
sibility for recontacting from clinicians to patients may be seen 
as promoting patient choice but may not necessarily eliminate 
a potential duty clinicians could have to recontact patients. 
(We follow the definition of “duty to recontact” given in the first 
systematic review of this issue.7 Such a duty is defined as the 
ethical and/or legal obligation to recontact former patients in 
light of new genetic information.)
Our data provide some insight into genetics service provid-
ers’ worries about legal consequences of implementing recon-
tacting systems. Specifically, some respondents expressed the 
concern that introducing recontacting systems would create a 
practice standard and that failure to recontact could then be 
seen as negligent.
It is important to point out that—although in the United 
Kingdom there is currently no statute law and professional 
guidance regarding recontacting, and although there have 
been no known litigation cases—the fact that some centers do 
recontact might be seen as creating a duty to do so. If recon-
tacting becomes standard practice, then patients who are not 
recontacted, and are thus not able to avail themselves of inter-
ventions that might benefit them, could claim that a reason-
able  health-care professional should provide this service and 
that the reasonable patient could expect it. Moreover, although 
there is no statute law or cases about recontact in genetics, 
there have been cases in North America relevant to recontact in 
other areas of medicine.16,17 It is difficult to determine whether 
concern about potential medicolegal consequences influences 
health-care professionals’ practices. We are exploring these 
issues in interviews that we are currently conducting with 
health-care professionals potentially involved in recontacting 
(clinical geneticists and other mainstream specialties) in the 
United Kingdom.
Limitations
There are some limitations of this study. Although we asked 
respondents to discuss the questions with their center’s clinical 
team before completing the survey, we cannot know whether 
they did. As genomics enters mainstream practice, it will be 
important to seek wider representations of professional views 
and experiences. To address these limitations, we are conduct-
ing further research to investigate the views of health-care 
professionals potentially involved in recontacting (including 
specialties other than clinical genetics), patients, and other 
stakeholders, such as patient-support groups.
This survey was administered in the United Kingdom and 
reports the views and concerns of genetics service providers 
working in this country. The medicolegal aspects of recontact-
ing and health-care professionals’ views on the issue are likely 
to be subtly different in other countries, especially where legal 
systems are different (e.g., Roman law as opposed to common 
law–based systems). It will be important to conduct a wider 
analysis to support recommendations or practice guidelines, if 
any, in this increasingly complex area of clinical practice.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
ACKNOWLEDGMENTS
The authors thank all of the clinical genetics staff who have par-
ticipated in the study to date. The project is funded by the Eco-
nomic and Social Research Council of the United Kingdom (grant 
reference: ES/L002868/1).
DISCLOSURE
The authors declare no conflict of interest.
REFERENCES
 1. Hunter, AGW, Sharpe NF, Mullen M, Meschino WS. Ethical, legal, and practical 
concerns about recontacting patients to inform them of new information: the 
case in medical genetics. In: Sharpe NF, Carter RF (eds). Genetic Testing: Care, 
Consent, and Liability. Wiley: Hoboken, NJ,2006.
 2. Burton H, Cole T and Fardon P. Genomics in medicine. delivering genomics 
through clinical practice. In: Report of the Joint Committee on Medical Genetics. 
2012. http://www.geneticseducation.nhs.uk/downloads/1386_Genomics_in_
Medicine_June_2012.pdf.
 Volume 18  |  Number 9  |  September 2016  |  GeNeTICs in MeDICINe
881
Recontact in clinical practice: a survey of clinical genetics services in the UK  |  CARRIERI et al Original research article
 3. Pyeritz RE. The coming explosion in genetic testing–is there a duty to recontact? 
N Engl J Med 2011;365:1367–1369.
 4. Rantanen E, Hietala M, Kristoffersson U, et al. Regulations and practices 
of genetic counselling in 38 European countries: the perspective of national 
representatives. Eur J Hum Genet 2008;16:1208–1216.
 5. Hirschhorn K, Fleisher LD, Godmilow L, et al. Duty to re-contact. Policy 
statement by the Social, Ethical, and Legal Issues Committee of the American 
College of Medical Geneticists. Genet Med 1999;1:171–172.
 6. Richards CS, Bale S, Bellissimo DB, et al.; Molecular Subcommittee of the 
ACMG Laboratory Quality Assurance Committee. ACMG recommendations 
for standards for interpretation and reporting of sequence variations: revisions 
2007. Genet Med 2008;10:294–300.
 7. Otten E, Plantinga M, Birnie E, et al. Is there a duty to recontact in light of 
new genetic technologies? A systematic review of the literature. Genet Med 
2015;17:668–678.
 8. Fitzpatrick JL, Hahn C, Costa T, Huggins MJ. The duty to recontact: attitudes of 
genetics service providers. Am J Hum Genet 1999;64:852–860.
 9. Dean JC, Fitzpatrick DR, Farndon PA, Kingstn H, Cusine D. Genetic registers 
in clinical practice: a survey of UK clinical genetics. J Med Genet 2000;37: 
636–640.
 10. Kausmeyer DT, Lengerich EJ, Kluhsman BC, Morrone D, Harper GR, Baker MJ. 
A survey of patients’ experiences with the cancer genetic counseling process: 
recommendations for cancer genetics programs. J Genet Couns 2006;15: 
409–431.
 11. Bernard LE, McGillivray B, Van Allen MI, Friedman JM, Langlois S. Duty to 
re-contact: a study of families at risk for Fragile X. J Genet Couns 1999;8:3–15.
 12. Sexton AC, Sahhar M, Thorburn DR, Metcalfe SA. Impact of a genetic diagnosis 
of a mitochondrial disorder 5-17 years after the death of an affected child. 
J Genet Couns 2008;17:261–273.
 13. Knoppers BM. Duty to recontact: a legal harbinger? Am J Med Genet 
2001;103:277.
 14. Sharpe NF. The duty to recontact: benefit and harm. Am J Hum Genet 
1999;65:1201–1204.
 15. Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and 
BRCA2 variants of unknown significance: variant reclassification and surgical 
decisions. Genet Med 2011;13:998–1005.
 16. Pelias MZ. Duty to disclose in medical genetics: a legal perspective. Am J Med 
Genet 1991;39:347–354.
 17. Hunter AG, Sharpe N, Mullen M, Meschino WS. Ethical, legal, and practical 
concerns about recontacting patients to inform them of new information: the 
case in medical genetics. Am J Med Genet 2001;103:265–276.
 18. Braun V and Clarke V. Using thematic analysis in psychology. Qual Res 
Psychology 2006;3: 77–101.
 19. Burton H, Alberg C, Stewart A. Mainstreaming genetics: a comparative review 
of clinical services for inherited cardiovascular conditions in the UK. Public 
Health Genomics 2010;13:235–245.
 20. van El CG, Cornel MC, Borry P, et al., Whole-genome sequencing in health care. 
Eur J Hum Genet 2013;21:S1–S5.
This work is licensed under a Creative Commons 
Attribution 4.0 International License. The images 
or other third party material in this article are included in the 
article’s Creative Commons license, unless indicated 
otherwise in the credit line; if the material is not included 
under the Creative Commons license, users will need to obtain 
permission from the license holder to reproduce the material. 
To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/
GeNeTICs in MeDICINe  |  Volume 18  |  Number 9  |  September 2016
